US EditionPublished • loading... • Updated
Rivalry Extends Closing Date for Non-Brokered Private Placement
BioVaxys will issue 1.79 million common shares valued at $0.23 each to settle $412,249 in debt, subject to regulatory and corporate approvals.
- On November 13, 2025, BioVaxys Technology Corp. agreed to issue up to 1,792,387 common shares at $0.23 each to settle $412,249 in accrued debt.
- Faced with outstanding liabilities, BioVaxys opted to issue shares to resolve creditor claims and conserve cash, pending corporate and regulatory approvals including Canadian Securities Exchange acceptance.
- All issued securities will be subject to a statutory hold period of four months and one day and will not be registered for sale in the United States, pending Canadian Securities Exchange acceptance.
- The deal changes the company's capital structure and may affect BioVaxys' ability to raise funding for clinical development, with its shares trading on the CSE, Frankfurt Bourse, and OTC Markets.
- The release cautions that forward-looking statements about the Debt Settlement involve regulatory approvals and assumptions, and BioVaxys does not update these except as required by law.
Insights by Ground AI
12 Articles
12 Articles
NiagaraFallsReview.ca+10 Reposted by 10 other sources
Rivalry Extends Closing Date for Non-Brokered Private Placement
TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the "Company" or "Rivalry") (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for digital-first players, is extending the closing date for the final tranche of its non-brokered…
·Niagara Falls, Canada
Read Full Article
Coverage Details
Total News Sources12
Leaning Left5Leaning Right2Center1Last UpdatedBias Distribution63% Left
Bias Distribution
- 63% of the sources lean Left
63% Left
L 63%
12%
R 25%
Factuality
To view factuality data please Upgrade to Premium
